Alkem Laboratories Limited

NSE ALKEM.NS

Alkem Laboratories Limited Operating Income Margin for the year ending March 31, 2024: 15.36%

Alkem Laboratories Limited Operating Income Margin is 15.36% for the year ending March 31, 2024, a 35.05% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Alkem Laboratories Limited Operating Income Margin for the year ending March 31, 2023 was 11.38%, a -31.40% change year over year.
Alkem Laboratories Limited Operating Income Margin for the year ending March 31, 2022 was 16.58%, a -13.53% change year over year.
Alkem Laboratories Limited Operating Income Margin for the year ending March 31, 2021 was 19.18%, a 24.09% change year over year.
Alkem Laboratories Limited Operating Income Margin for the year ending March 31, 2020 was 15.45%, a 19.24% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: ALKEM.NS

Alkem Laboratories Limited

CEO	Dr. Vikas Gupta
IPO Date	Dec. 23, 2015
Location	India
Headquarters	Devashish Building
Employees	17,432
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Key trends

Past 5 years